Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 1,622

The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.

The many faces of α-synuclein: from structure and toxicity to therapeutic target

Open access
Lashuel, Hilal A., Overk, Cassia R., Oueslati, Abid, Masliah, Eliezer·2013·Nature Reviews Neuroscience
DOI 10.1038/nrn3406
Open this paper in CoChat — free account

Abstract

Disorders characterized by α-synuclein (α-syn) accumulation, Lewy body formation and parkinsonism (and in some cases dementia) are collectively known as Lewy body diseases. The molecular mechanism (or mechanisms) through which α-syn abnormally accumulates and contributes to neurodegeneration in these disorders remains unknown. Here, we provide an overview of current knowledge and prevailing hypotheses regarding the conformational, oligomerization and aggregation states of α-syn and their role in regulating α-syn function in health and disease. Understanding the nature of the various α-syn structures, how they are formed and their relative contributions to α-syn-mediated toxicity may inform future studies aiming to develop therapeutic prevention and intervention.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/nrn3406

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 21 references

Research works printed but not linked: 110

  1. Vekrellis, K., Xilouri, M., Emmanouilidou, E., Rideout, H. J. & Stefanis, L. Pathological roles of α-synuclein in neurological disorders. Lancet Neurol. 10, 1015–1025 (2011). · DOI · Paper page
  2. Zarranz, J. J. et al. The new mutation, E46K, of α-synuclein causes Parkinson and Lewy body dementia. Ann. Neurol. 55, 164–173 (2004). · DOI · Paper page
  3. Simon-Sanchez, J. et al. Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nature Genet. 41, 1308–1312 (2009). · DOI · Paper page
  4. Conway, K. A., Harper, J. D. & Lansbury, P. T. Accelerated in vitro fibril formation by a mutant α-synuclein linked to early-onset Parkinson disease. Nature Med. 4, 1318–1320 (1998). · DOI · Paper page
  5. Oueslati, A., Fournier, M. & Lashuel, H. A. Role of post-translational modifications in modulating the structure, function and toxicity of α-synuclein: implications for Parkinson's disease pathogenesis and therapies. Prog. Brain Res. 183, 115–145 (2010). · DOI · Paper page
  6. Taschenberger, G. et al. Aggregation of α-synuclein promotes progressive in vivo neurotoxicity in adult rat dopaminergic neurons. Acta Neuropathol. 123, 671–683 (2011). · DOI
  7. Galvin, J. E., Lee, V. M. & Trojanowski, J. Q. Synucleinopathies: clinical and pathological implications. Arch. Neurol. 58, 186–190 (2001). · DOI · Paper page
  8. Wang, S. et al. α-Synuclein disrupts stress signaling by inhibiting polo-like kinase Cdc5/Plk2. Proc. Natl Acad. Sci. USA 109, 16119–16124 (2012). · DOI
  9. Jakes, R., Spillantini, M. G. & Goedert, M. Identification of two distinct synucleins from human brain. FEBS Lett. 345, 27–32 (1994). · DOI · Paper page
  10. Withers, G. S., George, J. M., Banker, G. A. & Clayton, D. F. Delayed localization of synelfin (synuclein, NACP) to presynaptic terminals in cultured rat hippocampal neurons. Brain Res. Dev. Brain Res. 99, 87–94 (1997). · DOI · Paper page
  11. Kahle, P. J. et al. Subcellular localization of wild-type and Parkinson's disease-associated mutant α-synuclein in human and transgenic mouse brain. J. Neurosci. 20, 6365–6373 (2000). · DOI · Paper page
  12. Lee, S. J., Jeon, H. & Kandror, K. V. α-synuclein is localized in a subpopulation of rat brain synaptic vesicles. Acta Neurobiol. Exp. 68, 509–515 (2008). · DOI
  13. Zhang, L. et al. Semi-quantitative analysis of α-synuclein in subcellular pools of rat brain neurons: an immunogold electron microscopic study using a C-terminal specific monoclonal antibody. Brain Res. 1244, 40–52 (2008). · DOI
  14. Cabin, D. E. et al. Synaptic vesicle depletion correlates with attenuated synaptic responses to prolonged repetitive stimulation in mice lacking α-synuclein. J. Neurosci. 22, 8797–8807 (2002). · DOI · Paper page
  15. Murphy, D. D., Rueter, S. M., Trojanowski, J. Q. & Lee, V. M. Synucleins are developmentally expressed, and α-synuclein regulates the size of the presynaptic vesicular pool in primary hippocampal neurons. J. Neurosci. 20, 3214–3220 (2000). · DOI · Paper page
  16. Yavich, L., Tanila, H., Vepsalainen, S. & Jakala, P. Role of α-synuclein in presynaptic dopamine recruitment. J. Neurosci. 24, 11165–11170 (2004). · DOI · Paper page
  17. Scott, D. A. et al. A pathologic cascade leading to synaptic dysfunction in α-synuclein-induced neurodegeneration. J. Neurosci. 30, 8083–8095 (2010). · DOI · Paper page
  18. Nemani, V. M. et al. Increased expression of α-synuclein reduces neurotransmitter release by inhibiting synaptic vesicle reclustering after endocytosis. Neuron 65, 66–79 (2010). This study found that α-syn overexpression inhibited neurotransmitter release by reducing the size of the synaptic vesicle recycling pool. · DOI · Paper page
  19. Gaugler, M. N. et al. Nigrostriatal overabundance of α-synuclein leads to decreased vesicle density and deficits in dopamine release that correlate with reduced motor activity. Acta Neuropathol. 123, 653–669 (2012). · DOI
  20. Lundblad, M., Decressac, M., Mattsson, B. & Bjorklund, A. Impaired neurotransmission caused by overexpression of α-synuclein in nigral dopamine neurons. Proc. Natl Acad. Sci. USA 109, 3213–3219 (2012). · DOI · Paper page
  21. Larsen, K. E. et al. α-synuclein overexpression in PC12 and chromaffin cells impairs catecholamine release by interfering with a late step in exocytosis. J. Neurosci. 26, 11915–11922 (2006). · DOI · Paper page
  22. Scott, D. & Roy, S. α-synuclein inhibits intersynaptic vesicle mobility and maintains recycling-pool homeostasis. J. Neurosci. 32, 10129–10135 (2012). · DOI
  23. Payton, J. E., Perrin, R. J., Woods, W. S. & George, J. M. Structural determinants of PLD2 inhibition by α-synuclein. J. Mol. Biol. 337, 1001–1009 (2004). · DOI
  24. Dalfo, E. & Ferrer, I. α-synuclein binding to rab3a in multiple system atrophy. Neurosci. Lett. 380, 170–175 (2005). · DOI
  25. Burre, J. et al. α-synuclein promotes SNARE-complex assembly in vivo and in vitro. Science 329, 1663–1667 (2010). This paper identifies α-synuclein as a non-classical chaperone that binds and promotes SNARE-complex assembly. · DOI · Paper page
  26. Chandra, S., Gallardo, G., Fernandez-Chacon, R., Schluter, O. M. & Sudhof, T. C. α-synuclein cooperates with CSPα in preventing neurodegeneration. Cell 123, 383–396 (2005). · DOI · Paper page
  27. Ueda, K. et al. Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease. Proc. Natl Acad. Sci. USA 90, 11282–11286 (1993). This is the first report of the NAC being a 140-amino-acid protein. · DOI · Paper page
  28. Ulmer, T. S., Bax, A., Cole, N. B. & Nussbaum, R. L. Structure and dynamics of micelle-bound human α-synuclein. J. Biol. Chem. 280, 9595–9603 (2005). · DOI · Paper page
  29. Eliezer, D., Kutluay, E., Bussell, R. Jr & Browne, G. Conformational properties of α-synuclein in its free and lipid-associated states. J. Mol. Biol. 307, 1061–1073 (2001). · DOI · Paper page
  30. Masliah, E., Iwai, A., Mallory, M., Ueda, K. & Saitoh, T. Altered presynaptic protein NACP is associated with plaque formation and neurodegeneration in Alzheimer's disease. Am. J. Pathol. 148, 201–210 (1996).
  31. Hashimoto, M., Takenouchi, T., Mallory, M., Masliah, E. & Takeda, A. The role of NAC in amyloidogenesis in Alzheimer's disease. Am. J. Pathol. 156, 734–736 (2000). · DOI
  32. El-Agnaf, O. M., Jakes, R., Curran, M. D. & Wallace, A. Effects of the mutations Ala30 to Pro and Ala53 to Thr on the physical and morphological properties of α-synuclein protein implicated in Parkinson's disease. FEBS Lett. 440, 67–70 (1998). · DOI · Paper page
  33. Luk, K. C. et al. Exogenous α-synuclein fibrils seed the formation of Lewy body-like intracellular inclusions in cultured cells. Proc. Natl Acad. Sci. USA 106, 20051–20056 (2009). These authors showed that α-syn seeds can recruit endogenous soluble α-syn protein to form pathological species. · DOI · Paper page
  34. Weinreb, P. H., Zhen, W., Poon, A. W., Conway, K. A. & Lansbury, P. T. Jr. NACP, a protein implicated in Alzheimer's disease and learning, is natively unfolded. Biochemistry 35, 13709–13715 (1996). · DOI · Paper page
  35. Fauvet, B. et al. α-synuclein in the central nervous system and from erythrocytes, mammalian cells and E. coli exists predominantly as a disordered monomer. J. Biol. Chem. 287, 15345–15364 (2012). This study reassessed the oligomeric state of α-syn and demonstrated that native α-syn exists predominantly as an unfolded monomer and not a tetramer. · DOI · Paper page
  36. Ramakrishnan, M., Jensen, P. H. & Marsh, D. Association of α-synuclein and mutants with lipid membranes: spin-label ESR and polarized IR. Biochemistry 45, 3386–3395 (2006). · DOI
  37. Ullman, O., Fisher, C. K. & Stultz, C. M. Explaining the structural plasticity of α-synuclein. J. Am. Chem. Soc. 133, 19536–19546 (2011). · DOI
  38. Hashimoto, M. et al. Oxidative stress induces amyloid-like aggregate formation of NACP/α-synuclein in vitro. Neuroreport 10, 717–721 (1999). · DOI · Paper page
  39. Andringa, G. et al. Tissue transglutaminase catalyzes the formation of α-synuclein crosslinks in Parkinson's disease. FASEB J. 18, 932–934 (2004). · DOI
  40. Paleologou, K. E. et al. Phosphorylation at S87 is enhanced in synucleinopathies, inhibits α-synuclein oligomerization, and influences synuclein-membrane interactions. J. Neurosci. 30, 3184–3198 (2010). · DOI · Paper page
  41. Li, W. et al. Aggregation promoting C-terminal truncation of α-synuclein is a normal cellular process and is enhanced by the familial Parkinson's disease-linked mutations. Proc. Natl Acad. Sci. USA 102, 2162–2167 (2005). · DOI · Paper page
  42. Dufty, B. M. et al. Calpain-cleavage of α-synuclein: connecting proteolytic processing to disease-linked aggregation. Am. J. Pathol. 170, 1725–1738 (2007). · DOI · Paper page
  43. Perrin, R. J., Woods, W. S., Clayton, D. F. & George, J. M. Exposure to long chain polyunsaturated fatty acids triggers rapid multimerization of synucleins. J. Biol. Chem. 276, 41958–41962 (2001). · DOI · Paper page
  44. Sharon, R. et al. The formation of highly soluble oligomers of α-synuclein is regulated by fatty acids and enhanced in Parkinson's disease. Neuron 37, 583–595 (2003). · DOI · Paper page
  45. Karube, H. et al. N-terminal region of α-synuclein is essential for the fatty acid-induced oligomerization of the molecules. FEBS Lett. 582, 3693–3700 (2008). · DOI
  46. Takeda, A. et al. Abnormal distribution of the non-Aβ component of Alzheimer's disease amyloid precursor/α-synuclein in Lewy body disease as revealed by proteinase K and formic acid pretreatment. Lab. Invest. 78, 1169–1177 (1998).
  47. Suh, Y. H. & Checler, F. Amyloid precursor protein, presenilins, and α-synuclein: molecular pathogenesis and pharmacological applications in Alzheimer's disease. Pharmacol. Rev. 54, 469–525 (2002). · DOI · Paper page
  48. Iwai, A. et al. The synaptic protein NACP is abnormally expressed during the progression of Alzheimer's disease. Brain Res. 720, 230–234 (1996). · DOI
  49. Kragh, C. L., Ubhi, K., Wyss-Corey, T. & Masliah, E. Autophagy in dementias. Brain Pathol. 22, 99–109 (2012). · DOI
  50. Seidel, K. et al. First appraisal of brain pathology owing to A30P mutant α-synuclein. Ann. Neurol. 67, 684–689 (2010). · DOI
  51. Maraganore, D. M. et al. Collaborative analysis of α-synuclein gene promoter variability and Parkinson disease. JAMA 296, 661–670 (2006). · DOI · Paper page
  52. Iwata, A. et al. α-synuclein degradation by serine protease neurosin: implication for pathogenesis of synucleinopathies. Hum. Mol. Genet. 12, 2625–2635 (2003). · DOI · Paper page
  53. Klucken, J., Shin, Y., Masliah, E., Hyman, B. T. & McLean, P. J. Hsp70 reduces α-synuclein aggregation and toxicity. J. Biol. Chem. 279, 25497–25502 (2004). · DOI · Paper page
  54. McNaught, K. S. et al. Impairment of the ubiquitin-proteasome system causes dopaminergic cell death and inclusion body formation in ventral mesencephalic cultures. J. Neurochem. 81, 301–306 (2002). · DOI · Paper page
  55. McNaught, K. S. et al. Proteasome inhibition causes nigral degeneration with inclusion bodies in rats. Neuroreport 13, 1437–1441 (2002). · DOI · Paper page
  56. Desplats, P. et al. Inclusion formation and neuronal cell death through neuron-to-neuron transmission of α-synuclein. Proc. Natl Acad. Sci. USA 106, 13010–13015 (2009). · DOI · Paper page
  57. Crews, L. et al. Selective molecular alterations in the autophagy pathway in patients with Lewy body disease and in models of α-synucleinopathy. PLoS ONE 5, e9313 (2010). · DOI · Paper page
  58. Kosaka, K. Diffuse Lewy body disease in Japan. J. Neurol. 237, 197–204 (1990). · DOI · Paper page
  59. Dickson, D. W. et al. Diffuse Lewy body disease: light and electron microscopic immunocytochemistry of senile plaques. Acta Neuropathol. 78, 572–584 (1989). · DOI · Paper page
  60. Kahle, P. J. et al. Selective insolubility of α-synuclein in human Lewy body diseases is recapitulated in a transgenic mouse model. Am. J. Pathol. 159, 2215–2225 (2001). · DOI · Paper page
  61. Baba, M. et al. Aggregation of α-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. Am. J. Pathol. 152, 879–884 (1998).
  62. Lee, M. K. et al. Human α-synuclein-harboring familial Parkinson's disease-linked Ala-53 → Thr mutation causes neurodegenerative disease with α-synuclein aggregation in transgenic mice. Proc. Natl Acad. Sci. USA 99, 8968–8973 (2002). · DOI · Paper page
  63. Tsigelny, I. F. et al. Role of α-synuclein penetration into the membrane in the mechanisms of oligomer pore formation. FEBS J. 279, 1000–1013 (2012). Computational modelling shows that α-synuclein can form ring-like structures that penetrate the membrane. · DOI · Paper page
  64. Bellucci, A., Navarria, L., Zaltieri, M., Missale, C. & Spano, P. α-synuclein synaptic pathology and its implications in the development of novel therapeutic approaches to cure Parkinson's disease. Brain Res. 1432, 95–113 (2012). · DOI
  65. Garcia-Reitbock, P. et al. SNARE protein redistribution and synaptic failure in a transgenic mouse model of Parkinson's disease. Brain 133, 2032–2044 (2010). · DOI · Paper page
  66. Horvath, I. et al. Mechanisms of protein oligomerization: inhibitor of functional amyloids templates α-synuclein fibrillation. J. Am. Chem. Soc. 134, 3439–3444 (2012). · DOI
  67. Conway, K. A. et al. Accelerated oligomerization by Parkinson's disease linked α-synuclein mutants. Ann. NY Acad. Sci. 920, 42–45 (2000). · DOI · Paper page
  68. Cremades, N. et al. Direct observation of the interconversion of normal and toxic forms of α-synuclein. Cell 149, 1048–1059 (2012). · DOI · Paper page
  69. Danzer, K. M. et al. Different species of α-synuclein oligomers induce calcium influx and seeding. J. Neurosci. 27, 9220–9232 (2007). · DOI · Paper page
  70. Iwatsubo, T. Pathological biochemistry of α-synucleinopathy. Neuropathology 27, 474–478 (2007). · DOI
  71. Oueslati, A., Paleologou, K. E., Schneider, B. L., Aebischer, P. & Lashuel, H. A. Mimicking phosphorylation at serine 87 inhibits the aggregation of human α-synuclein and protects against its toxicity in a rat model of Parkinson's disease. J. Neurosci. 32, 1536–1544 (2012). · DOI
  72. Souza, J. M., Giasson, B. I., Chen, Q., Lee, V. M. & Ischiropoulos, H. Dityrosine cross-linking promotes formation of stable α-synuclein polymers. Implication of nitrative and oxidative stress in the pathogenesis of neurodegenerative synucleinopathies. J. Biol. Chem. 275, 18344–18349 (2000). · DOI · Paper page
  73. Uversky, V. N., Li, J. & Fink, A. L. Metal-triggered structural transformations, aggregation, and fibrillation of human α-synuclein — a possible molecular link between Parkinson's disease and heavy metal exposure. J. Biol. Chem. 276, 44284–44296 (2001). · DOI · Paper page
  74. Conway, K. A., Rochet, J. C., Bieganski, R. M. & Lansbury, P. T. Jr. Kinetic stabilization of the α-synuclein protofibril by a dopamine-α-synuclein adduct. Science 294, 1346–1349 (2001). · DOI · Paper page
  75. Conway, K. A. et al. Acceleration of oligomerization, not fibrillization, is a shared property of both α-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. Proc. Natl Acad. Sci. USA 97, 571–576 (2000). · DOI · Paper page
  76. Hsu, L. J. et al. α-synuclein promotes mitochondrial deficit and oxidative stress. Am. J. Pathol. 157, 401–410 (2000). · DOI · Paper page
  77. Hashimoto, M. et al. The role of α-synuclein assembly and metabolism in the pathogenesis of Lewy body disease. J. Mol. Neurosci. 24, 343–352 (2004). · DOI
  78. Alim, M. A. et al. Demonstration of a role for α-synuclein as a functional microtubule-associated protein. J. Alzheimers Dis. 6, 435–442 (2004). · DOI
  79. da Silveira, S. A. et al. Phosphorylation does not prompt, nor prevent, the formation of α-synuclein toxic species in a rat model of Parkinson's disease. Hum. Mol. Genet. 18, 872–887 (2009).
  80. Gorbatyuk, O. S. et al. The phosphorylation state of Ser-129 in human α-synuclein determines neurodegeneration in a rat model of Parkinson disease. Proc. Natl Acad. Sci. USA 105, 763–768 (2008). · DOI · Paper page
  81. Winner, B. et al. In vivo demonstration that α-synuclein oligomers are toxic. Proc. Natl Acad. Sci. USA 108, 4194–4199 (2011). · DOI · Paper page
  82. Jan, A. et al. Aβ42 neurotoxicity is mediated by ongoing nucleated polymerization process rather than by discrete Aβ42 species. J. Biol. Chem. 286, 8585–8596 (2011). · DOI · Paper page
  83. Wogulis, M. et al. Nucleation-dependent polymerization is an essential component of amyloid-mediated neuronal cell death. J. Neurosci. 25, 1071–1080 (2005). · DOI · Paper page
  84. Colla, E. et al. Accumulation of toxic α-synuclein oligomer within endoplasmic reticulum occurs in α-synucleinopathy in vivo. J. Neurosci. 32, 3301–3305 (2012). · DOI · Paper page
  85. Danzer, K. M. et al. Heat-shock protein 70 modulates toxic extracellular α-synuclein oligomers and rescues trans-synaptic toxicity. FASEB J. 25, 326–336 (2011). · DOI · Paper page
  86. Alvarez-Erviti, L. et al. Lysosomal dysfunction increases exosome-mediated α-synuclein release and transmission. Neurobiol. Dis. 42, 360–367 (2011). · DOI · Paper page
  87. Lee, H. J. et al. Assembly-dependent endocytosis and clearance of extracellular α-synuclein. Int. J. Biochem. Cell. Biol. 40, 1835–1849 (2008). · DOI · Paper page
  88. Jao, C. C., Hegde, B. G., Chen, J., Haworth, I. S. & Langen, R. Structure of membrane-bound α-synuclein from site-directed spin labeling and computational refinement. Proc. Natl Acad. Sci. USA 105, 19666–19671 (2008). · DOI · Paper page
  89. Volpicelli-Daley, L. A. et al. Exogenous α-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death. Neuron 72, 57–71 (2011). · DOI · Paper page
  90. Crews, L. et al. α-synuclein alters Notch-1 expression and neurogenesis in mouse embryonic stem cells and in the hippocampus of transgenic mice. J. Neurosci. 28, 4250–4260 (2008). · DOI
  91. Letarov, A., Manival, X., Desplats, C. & Krisch, H. M. gpwac of the T4-type bacteriophages: structure, function, and evolution of a segmented coiled-coil protein that controls viral infectivity. J. Bacteriol. 187, 1055–1066 (2005). · doi:10.1128/jb.187.3.1055-1066.2005
  92. Ekberg, H. et al. The specific monocarboxylate transporter-1 (MCT-1) inhibitor, AR-C117977, induces donor-specific suppression, reducing acute and chronic allograft rejection in the rat. Transplantation 84, 1191–1199 (2007). · DOI
  93. Karlsson, J., Petersen, A., Gido, G., Wieloch, T. & Brundin, P. Combining neuroprotective treatment of embryonic nigral donor tissue with mild hypothermia of the graft recipient. Cell Transplant. 14, 301–309 (2005). · DOI
  94. Karlsson, J., Emgard, M., Gido, G., Wieloch, T. & Brundin, P. Increased survival of embryonic nigral neurons when grafted to hypothermic rats. Neuroreport 11, 1665–1668 (2000). · doi:10.1097/00001756-200006050-00014
  95. Frodl, E. M., Duan, W. M., Sauer, H., Kupsch, A. & Brundin, P. Human embryonic dopamine neurons xenografted to the rat: effects of cryopreservation and varying regional source of donor cells on transplant survival, morphology and function. Brain Res. 647, 286–298 (1994). · doi:10.1016/0006-8993(94)91328-5
  96. Kordower, J. H., Freeman, T. B. & Olanow, C. W. Neuropathology of fetal nigral grafts in patients with Parkinson's disease. Mov. Disord. 13, 88–95 (1998). · DOI · Paper page
  97. Tang, B. et al. Forkhead box protein p1 is a transcriptional repressor of immune signaling in the CNS: implications for transcriptional dysregulation in Huntington disease. Hum. Mol. Genet. 21, 3097–3111 (2012). · DOI
  98. Nonaka, T., Watanabe, S. T., Iwatsubo, T. & Hasegawa, M. Seeded aggregation and toxicity of α-synuclein and tau: cellular models of neurodegenerative diseases. J. Biol. Chem. 285, 34885–34898 (2010). · DOI · Paper page
  99. Luk, K. C. et al. Intracerebral inoculation of pathological α-synuclein initiates a rapidly progressive neurodegenerative α-synucleinopathy in mice. J. Exp. Med. 209, 975–986 (2012). · DOI · Paper page
  100. Ban, T. et al. Direct observation of Aβ amyloid fibril growth and inhibition. J. Mol. Biol. 344, 757–767 (2004). · DOI · Paper page
  101. Lashuel, H. A. et al. New class of inhibitors of amyloid-β fibril formation. Implications for the mechanism of pathogenesis in Alzheimer's disease. J. Biol. Chem. 277, 42881–42890 (2002). · DOI
  102. Di Giovanni, S. et al. Entacapone and tolcapone, two catechol O-methyltransferase inhibitors, block fibril formation of α-synuclein and β-amyloid and protect against amyloid-induced toxicity. J. Biol. Chem. 285, 14941–14954 (2010). · DOI
  103. Masuda, M. et al. Small molecule inhibitors of α-synuclein filament assembly. Biochemistry 45, 6085–6094 (2006). · DOI · Paper page
  104. Porat, Y., Abramowitz, A. & Gazit, E. Inhibition of amyloid fibril formation by polyphenols: structural similarity and aromatic interactions as a common inhibition mechanism. Chem. Biol. Drug Des. 67, 27–37 (2006). · DOI · Paper page
  105. Ayrolles-Torro, A. et al. Oligomeric-induced activity by thienyl pyrimidine compounds traps prion infectivity. J. Neurosci. 31, 14882–14892 (2011). · DOI
  106. Hirohata, M., Ono, K., Morinaga, A. & Yamada, M. Non-steroidal anti-inflammatory drugs have potent anti-fibrillogenic and fibril-destabilizing effects for α-synuclein fibrils in vitro. Neuropharmacology 54, 620–627 (2008). · DOI
  107. Fauvet, B. et al. Semisynthesis and characterization of N-terminally acetylated α-synuclein: implications for aggregation and cellular properties. J. Biol. Chem. 287, 28243–2862 (2012). · DOI
  108. Shaikh, S. & Nicholson, L. F. Advanced glycation end products induce in vitro cross-linking of α-synuclein and accelerate the process of intracellular inclusion body formation. J. Neurosci. Res. 86, 2071–2082 (2008). · DOI
  109. Hashimoto, M., Takeda, A., Hsu, L. J., Takenouchi, T. & Masliah, E. Role of cytochrome c as a stimulator of α-synuclein aggregation in Lewy body disease. J. Biol. Chem. 274, 28849–28852 (1999). · DOI · Paper page
  110. Lashuel, H. A., Hartley, D., Petre, B. M., Walz, T. & Lansbury, P. T. Jr. Neurodegenerative disease: amyloid pores from pathogenic mutations. Nature 418, 291 (2002). · DOI · Paper page

Cited by

See all 1,622

Metadata

Authors
Lashuel, H. A., Overk, C. R., Oueslati, A., & Masliah, E.
Venue
Nature Reviews Neuroscience
Publisher
Springer Science and Business Media LLC
Published
2012-12-20
Volume
14
Issue
1
Pages
38-48
ISSN
  • 1471-003X (ISSN-L)
  • 1471-0048
DOI
10.1038/nrn3406
OpenAlex
W1979591162
Cited by
1,622
References
21
FWCI
11.67
Type
journal article
Language
en
Open access
bronze
Licence
www.springer.com/tdm (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The many faces of α-synuclein: from structure and toxicity to therapeutic target. https://app.cochat.ai/papers/10.1038/nrn3406
The paper
Lashuel, H. A., Overk, C. R., Oueslati, A., & Masliah, E. (2013). The many faces of α-synuclein: from structure and toxicity to therapeutic target. Nature Reviews Neuroscience. https://doi.org/10.1038/nrn3406

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.